Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Smithkline Beecham Corporation

Zehong Wan

James Francis Callahan

Hongxing Yan

Xiaomin Zhang

Michael R Palovich

Yingxia Sang

Jian Wang

Jeffrey Charles Boehm

Xichen Lin

Xiao Ding

Eric Steven Manas

Kai Long

Yun Jin

Chongjie Zhu

Luigi Piero Stasi

Qing Shan Zhang

Paul Bamborough

Vipulkumar Kantibhai Patel

Anthony William James Cooper

Christopher E Neipp

Qian Liu

Dramane Ibrahim Laine

Beth Adams Norton

Jakob Busch-Petersen

Joseph E Pero

Matthew Robert Sender

Guoliang Lin

Stefano Livia

Neysa Nevins

Colin Michael Edge

Raphael Anthony Rivero

Baowei Zhao

Qing Feng Zhang

Katherine L Widdowson

Feng Ren

Joelle Lorraine Burgess

Cheng Peng

Krista B Goodman

Weiqiang Xing

Hailong Wang

Yimin Hu

Yang Zhan

Zhaolong Tong

Haihua Yu

Xiaobo Su

Sarah E Dowdell

Qiongfeng Xu

Qing Zhang

Christopher Ernst Neipp

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example Alzheimer's disease.

Compounds

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

LRRK2 inhibitors for the treatment of Parkinson's disease

Compounds as LRRK2 kinase inhibitors

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

[object Object]

The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2

The present invention relates to bicyclic[]imidazo pyrimidone compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease. In one aspect, this invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein different R groups are defined in the patent application.

Disclosed are 2,3-dihydroimiazo[1,2-c]pyrimidin-5(IH)-one compounds that inhibit Lp-PLA,processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors

Tricyclic compounds, preparation methods, and their uses

Growing community of inventors

Shanghai, China

Zehong Wan